Collector
Giriş Yap
GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn | Collector
GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn

GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn

Nuvalent's key asset is a drug called neladalkib, a therapy which targets certain types of lung cancer.

Go to News Site